MTHFD1L

The Mitochondrial Folate Link to Heart Disease

Most people associate folate metabolism with the MTHFR enzyme in the cytoplasm. But
folate cycling actually begins in the mitochondria, and a second enzyme —
MTHFD1L, the mitochondrial C1-tetrahydrofolate synthase |
it catalyzes the conversion of 10-formyl-THF back to formate plus free THF in
mitochondria, releasing one-carbon units for export to the cytoplasm — does much of the critical upstream
work. rs6922269 is an intronic variant in MTHFD1L that became one of the first
confirmed genetic loci for coronary artery disease (CAD) when it reached genome-wide
significance in the landmark 2007 WTCCC study.

The Mechanism

MTHFD1L sits at the interface of mitochondrial and cytoplasmic one-carbon metabolism.
Inside the mitochondrion, serine and glycine donate one-carbon units that are
progressively oxidized through a series of folate-bound intermediates.
MTHFD1L catalyzes the final step, releasing formate from 10-formyl-THF
| the resulting free tetrahydrofolate is recycled within the mitochondrion,
while formate is exported through the inner mitochondrial membrane to the cytoplasm. In the cytoplasm, this formate
is the primary one-carbon donor for purine synthesis, thymidylate synthesis,
and — critically — the remethylation of homocysteine to methionine via the
methyl cycle.

rs6922269 lies in intron 11 of MTHFD1L. Although the precise functional mechanism
by which this intronic variant alters enzyme activity or expression has not been
fully characterized, reduced MTHFD1L formate output would restrict cytoplasmic
one-carbon availability. This would limit methylation capacity and homocysteine
remethylation — a plausible biological link to cardiovascular risk. However,
studies to date have not found a statistically significant association between
rs6922269 genotype and plasma homocysteine levels, suggesting the cardiovascular
mechanism may be more nuanced or may act through folate-dependent purine synthesis
pathways rather than homocysteine elevation alone.

A distinctive feature of this variant is its association with lower
active vitamin B12 (holotranscobalamin) | the biologically available fraction of
serum B12 that is bound to transcobalamin II and can enter cells; only about
20-30% of total serum B12 is in this active form.
The AA genotype was associated with significantly lower baseline active B12 in ACS
patients even after adjustment for age and hypertensive status — pointing to an
interplay between MTHFD1L function, mitochondrial one-carbon metabolism, and B12
bioavailability.

The Evidence

The foundational evidence comes from Samani et al. 2007 |
a joint analysis of two genome-wide association studies: the Wellcome Trust Case
Control Consortium (WTCCC, ~2,000 CAD cases and ~3,000 controls) and the German
Myocardial Infarction Family Study (~875 early-onset MI cases and ~1,644 controls). rs6922269 on chromosome 6q25.1 reached
genome-wide significance (combined P=2.9×10⁻⁸) with a per-allele odds ratio of
1.23 (95% CI 1.15–1.33) for the A allele. At the time, it was one of only a small
number of variants meeting genome-wide significance for CAD beyond the 9p21 locus.

The CAD association was extended to post-event prognosis in a cohort study of
1,940 patients with acute coronary syndromes in the Coronary Disease Cohort Study (CDCS) |
with a validation cohort of 842 post-myocardial infarction patients. AA homozygotes had significantly higher
all-cause mortality at follow-up (19.6%) compared to GA (12.0%) and GG carriers (11.6%),
a difference that remained after Cox adjustment for established ACS risk factors
(P=0.03). However, the association was not validated in the independent PMI cohort,
limiting the strength of this prognostic finding.

A Czech cohort analysis of 2,117 ACS patients (1,614 men, 503 women) followed for
7 years | compared with 2,559 population-based controls; genotype frequencies were
similar between ACS patients and controls, suggesting the variant may influence
prognosis more than incidence in this population found a striking sex-specific effect:
AA genotype predicted cardiovascular mortality in males (OR 2.52, 95% CI 1.40–4.55,
P<0.001) but not in females. This sex-specific finding is preliminary and awaits
independent replication in a larger mixed-sex cohort.

Earlier screening of 95 GWAS-identified CAD variants for post-ACS mortality in
811 white ACS patients | from a prospective Australian cohort found rs6922269 to be the only variant
achieving statistical significance, with a 2.6-fold mortality hazard (P=0.007 after
adjustment for other ACS risk factors) — consistent with the CDCS findings.

Taken together, the evidence supports rs6922269 as a robust GWAS-identified CAD
susceptibility locus with an emerging prognostic role, particularly for
post-ACS mortality in males.

Practical Actions

Because the mechanism involves mitochondrial folate metabolism and active B12 handling,
ensuring optimal status of folate (as methylfolate rather than synthetic folic acid)
and active B12 (measured as holotranscobalamin rather than total serum B12) is the
most evidence-aligned response. The AA genotype's association with lower active B12
suggests that tracking holotranscobalamin specifically — not just total B12 — gives
a more accurate picture of B12 status in this context.

Plasma homocysteine monitoring is warranted as a functional marker of the
methylation/remethylation pathway, even though rs6922269 itself has not shown a
direct homocysteine association in studies to date. Any elevation in homocysteine
would confirm downstream insufficiency in this pathway and sharpen the intervention.

Interactions

rs6922269 is in a distinct LD block from rs2073067, the MTHFD1L variant associated
with Alzheimer's disease and altered plasma homocysteine. These two variants tag
different haplotypes within the same gene and their effects may be partially independent.
Carriers of risk alleles at both loci may face a compounded reduction in MTHFD1L
mitochondrial formate output, warranting attention to both cardiovascular and
neurocognitive folate-pathway monitoring.

The common MTHFR C677T (rs1801133) | reduces cytoplasmic MTHFR enzyme activity,
raising homocysteine and reducing methylation capacity
variant compounds the upstream mitochondrial restriction that rs6922269 may impose:
if both mitochondrial formate supply (MTHFD1L) and cytoplasmic folate processing
(MTHFR) are impaired, the cumulative effect on homocysteine and methylation capacity
is likely larger than either variant alone. This combination is a strong candidate
for a compound action.

The MTHFD1L splicing variant rs3832406 affects mRNA splicing efficiency and is
associated with neural tube defect risk in a separate LD block from rs6922269.